ITCC - Innovative Therapies for Children with Cancer in Europe

A Phase I/II Study of the Oral TRK Inhibitor LOXO 101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies

Pilot study of nivolumab in paediatric patients with hypermutant cancers

Ibrutinib randomized safety and efficacy study in pediatric patients with mature B-cell NHL, including Burkitt lymphoma/Leukemia and Diffuse Large B-cell Lymphoma

A phase I/II, multi-center, dose-escalating study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of Quizartinib administered in combination with re-induction chemotherapy, and as a single-agent maintenance therapy

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric Patients with Select Relapsed or Refractory Malignancies

An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age with Relapsed/Refractory Precursor B-cell or T cell Acute Lymphoblastic Leukemia

Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with PD or as consolidative immunotherapy in patients in CR after relapse